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Regular Article
PLATELETS AND THROMBOPOIESIS
Arf6 controls platelet spreading and clot retraction via integrin
aIIbb3 trafficking
Yunjie Huang,1 Smita Joshi,1 Binggang Xiang,2 Yasunori Kanaho,3 Zhenyu Li,2 Beth A. Bouchard,4 Carole L. Moncman,1
and Sidney W. Whiteheart1
1Department of Molecular and Cellular Biochemistry and 2Division of Cardiovascular Medicine, Saha Cardiovascular Research Center, University of
Kentucky, Lexington, KY; 3Department of Physiological Chemistry, University of Tsukuba, Tsukuba, Ibaraki, Japan; and 4Department of Biochemistry,
University of Vermont, Burlington, VT
Key Points
• Arf6 selectively regulates
endocytic trafficking of
platelet aIIbb3.
• Endocytosis contributes to
acute platelet function.
Platelet and megakaryocyte endocytosis is important for loading certain granule cargo
(ie, fibrinogen [Fg] and vascular endothelial growth factor); however, the mechanisms
of platelet endocytosis and its functional acute effects are understudied. Adenosine
5’-diphosphate–ribosylation factor 6 (Arf6) is a small guanosine triphosphate–binding
protein that regulates endocytic trafficking, especially of integrins. To study platelet
endocytosis, we generated platelet-specific Arf6 knockout (KO) mice. Arf6 KO platelets
had less associated Fg suggesting that Arf6 affects aIIbb3-mediated Fg uptake and/or
storage. Other cargo was unaffected. To measure Fg uptake, mice were injected with
biotinylated- or fluorescein isothiocyanate (FITC)–labeled Fg. Platelets from the injectedArf6 KOmice showed lower accumulation
of tagged Fg, suggesting an uptake defect. Ex vivo, Arf6 KO platelets were also defective in FITC-Fg uptake and storage.
Immunofluorescence analysis showed initial trafficking of FITC-Fg to a Rab4-positive compartment followed by colocalization
with Rab11-positive structures, suggesting that platelets contain and use both early and recycling endosomes. Resting and
activatedaIIbb3 levels, asmeasured by flow cytometry, were unchanged; yet, Arf6 KOplatelets exhibited enhanced spreading on
Fgand faster clot retraction. Thiswasnot the result of alterations inaIIbb3 signaling, becausemyosin light-chain phosphorylation
andRac1/RhoA activationwere unaffected. Consistent with the enhanced clot retraction and spreading, Arf6 KOmice showed no
deficits in tail bleeding or FeCl3-induced carotid injury assays. Our studies present the first mouse model for defining the
functions of platelet endocytosis and suggest that altered integrin traffickingmay affect the efficacy of platelet function. (Blood.
2016;127(11):1459-1467)
Introduction
It is increasingly clear that platelets are capable of different types of
intracellular membrane trafficking. Platelet exocytosis and autophagy
are critical for hemostasis.1-4 Platelet endocytosis is important for
granule cargo loading. Platelets selectively take up certain cargo (ie,
fibrinogen [Fg] and vascular endothelial growth factor) from plasma
and package it into a-granules.5-8 However, the molecular mecha-
nisms of platelet endocytosis are largely unknown. It is also unclear
whether platelet endocytosis contributes to acute platelet functions
beyond granule cargo loading. The goal of this study is to begin to
address these fundamental questions.
TheRas-like, small guanosine triphosphate (GTP)–bindingproteins
called adenosine 5’-diphosphate–ribosylation factors (Arf’s), are key
intracellular trafficking regulators. They cycle between inactive
guanosine diphosphate (GDP)–bound and active GTP-bound states
and are important for multiple functions (eg, actin cytoskeleton
remodeling, lipid metabolism, and vesicle trafficking).9,10 Arf1, 3,
and 6 are present in platelets.11,12 Previously, we showed that Arf6
rapidly converts from the GTP- to GDP-bound state upon platelet
activation.12,13 A second wave of activation, mediated via integrin
outside-in signaling, suppresses returnofArf6-GTP.Using inhibitory,
membrane-permeant, myristoylated Arf6 peptides, we demonstrated
that Arf6 affected human platelet adhesion and spreading.12 Arf6
also appears to play a role in the endocytosis and resensitization of
P2Y receptors.14 Taken together, these data suggest that Arf6
controls endocytic trafficking in a manner that may be responsive to
both initial platelet activation and subsequent signaling from contact-
mediated pathways. The goal of this study was to further understand
the action of Arf6 in platelets.
The integrin aIIbb3 plays an essential role in platelet adhesion and
aggregation.15,16 Also, it mediates plasma Fg endocytosis and storage
into a-granules by megakaryocytes and platelets.7,17,18 Although
unknown in platelets, Arf6 clearly affects integrin trafficking in other
cells: both endocytosis and recycling.19-21 In cancer cells, active and
inactive b1 integrins traffic via different endocytic recycling routes,
although their endocytosis equally requires both clathrin and
dynamin.22 Integrins can be recycled back to the plasma membrane,
either via aRab4-mediated short loop, recycling fromearlyendosomes,
or via a Rab11-mediated long loop, recycling from a perinuclear
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recycling compartment. These integrin recycling routes are critical for
cell adhesion and for directional migration.23,24 It has been suggested
that traffickingofaIIbb3 bound to Fg couldmodulate platelet function.
25
Based on its role in nucleated cells, we asked if Arf6 could modulate
membrane trafficking and whether that was important in platelets.
To probe Arf6’s role, we generated platelet-specific Arf6 knockout
(KO) mice. Deletion of Arf6 decreased Fg content by ;50%,
suggesting that Arf6 is involved in Fg uptake and/or storage by
controlling aIIbb3 trafficking. This conclusion was supported by the
impaired uptake of biotinylated human Fg (biotin-Fg) and fluorescein
isothiocyanate (FITC)–Fg in vivo and of FITC-Fg ex vivo. The levels
of other cargo were unaffected, suggesting a specific role for Arf6 in
aIIbb3/Fg trafficking. Consistent with the importance of aIIbb3
trafficking, Arf6 KO platelets showed enhanced clot retraction and
spreading on Fg, but this did not overtly increase thrombosis or
hemostasis. This is the first report, using a transgenic mouse model,
that aIIbb3 trafficking is affected by Arf6 in platelets and that this
regulation contributes to acute platelet functions. Furthermore, our
Arf6 KO mice should prove to be invaluable in studying other
endocytic trafficking processes in platelets.
Methods
Somemethods are described in detail in the supplementalMaterials andMethods
(available on the BloodWeb site).
Mouse generation and genotyping
Arf6flox/flox mice26 were crossed with PF4-promoter-driven Cre-recombinase
transgenic mice (Dr Radek Skoda, University Hospital, Basel, Switzerland).27
Each animal was genotyped by polymerase chain reaction using DNA from
tail biopsies. For the floxed Arf6 gene, the following primer set was used:
forward primer 59-GACCCCATGAGTGTTGTCAC-39 and reverse primer
59-GGGATACATAGAGAAACCTTGTCTCAGG-39. Detection of the
PF4-Cre transgene was as described.28
Flow cytometry analysis
To measure the surface levels of total and activated aIIbb3, washed platelets
(53107/mL)were either kept restingor stimulatedwith thrombin (0.1U/mL) for
1 minute. The reactions were stopped with hirudin (twofold excess) and incu-
batedwithFITC-anti-CD41/61antibodyandphycoerythrin-Jon/Aantibody.The
mixturewas analyzedbyfluorescence-activated cell sorter (FACS)asdescribed.2
To measure FITC-Fg binding, platelets (5.03 108/mL) were incubated, on
ice, with 0.06 or 0.12 mg/mL FITC-Fg for 20 minutes. Platelets were fixed with
2%paraformaldehyde and analyzedbyFACS.Thedifferenceof geometricmean
fluorescence intensity (GMFI) before and after trypan blue addition was used to
assess surface Fg binding (0.04% trypan blue quenched.95% of free FITC-Fg
fluorescence; supplemental Figure 1).29
To study FITC-Fg endocytosis at early time points, washed platelets
(1.03 109/mL) were incubated with FITC-Fg (0.15 mg/mL) at 37°C for the
indicated times. The platelets were fixed with 2% paraformaldehyde and
analyzed by FACS after addition of trypan blue.
To study the effect of myr-Arf peptides12,13 on FITC-Fg endocytosis by
human platelets, washed platelets (5.03 108/mL) were pretreated with peptides
for 5 minutes and then incubated with FITC-Fg (0.05 mg/mL) for the indicated
times. Platelets were fixed with 2% paraformaldehyde and GMFI after trypan
blue (1%) addition was used to assess the endocytosis of FITC-Fg.
Static platelet adhesion and platelet spreading
Platelet adhesion and spreading were performed as described by Ye et al2 and
detailed in the supplemental Materials and Methods. Briefly, for platelet
adhesion, calcein labeledplateletswere seededontoFg- orbovine serumalbumin
(BSA)–coated plates for 30 minutes at 37°C. Adherent platelets were quantified
with a fluorescence plate reader. For platelet spreading, platelets were incubated
on different surfaces at 37°C for increasing times. The adherent platelets were
fixed, imagedusingdifferential interference contrast (DIC)microscopy, and their
areas were measured using Image J (v1.47; National Institutes of Health).
Clot retraction
Washedplatelets (33108/mL) inN-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid (HEPES) Tyrode buffer (pH7.4) with human Fg (0.5mg/mL; Sigma) and
1mMCaCl2were incubated in cuvetteswith thrombin (0.1U/mL), and images
were taken at increasing times. Clot sizes were measured using Image
J software (v1.47; National Institutes of Health), and the percentage of clot size
relative to initial suspension volume was determined.
Biotin-Fg or FITC-Fg uptake in vivo
Biotin-Fg was prepared following manufacturer’s instructions using
EZ-LinkTM sulfo-NHS-Biotinylation Kit (Thermo Scientific). Mice were
injectedwith the indicated amounts of modified Fg via retro-orbital sinus and,
after 24 hours, were euthanized. To study the uptake of biotin-Fg, platelets
were harvested for analysis bywestern blotting. To study the in vivo uptake of
FITC-Fg, platelets and bonemarrow cellswere harvested. Plateletswerefixed
directly with 2% paraformaldehyde at room temperature. In contrast, bone
marrow cells were first stained with vioblue-conjugated anti-CD41 antibody,
and then fixed. Cells were viewed using a Nikon Eclipse E600 microscope,
and images were taken with an AxioCam MR camera (Zeiss, Germany) and
processed using Zen 2011 Digital Imaging software (Zeiss).
FITC-Fg uptake ex vivo
Washed platelets (53 108/mL) were incubated with FITC-Fg (0.05mg/mL) for
1 hour at 37°C. Platelets were recovered and resuspended in platelet poor plasma
or HEPES Tyrode buffer (pH 7.4) containing 0.35%BSA and 1 mMCaCl2 and
then incubated for 2 hours at 37°C and fixed. Platelets were mixed with trypan
blue (0.1%), prior to imaging. The number of FITC-positive puncta per platelet
was counted.
Immunofluorescence confocal microscopy
Washed platelets (5 3 108/mL) were incubated with or without FITC-Fg
(0.05 mg/mL) for the indicated times and fixed at room temperature. Platelets
were washed once with phosphate-buffered saline (PBS) and then allowed to
adhere to a poly-D-lysine (0.1 mg/mL)–coated surface. Platelets were washed
once with PBS, reduced with 0.1% NaBH4 for 10 minutes at room temperature,
washed again 33 5 minutes with PBS, and then permeabilized for 15 minutes
with 0.2%TritonX-100/PBS.After blocking (10%fetal bovine serum[FBS] and
0.05% Triton X-100 in PBS) for .90 minutes at room temperature, platelets
were incubated with primary antibody prepared with 5% FBS and 0.05% Triton
X-100 in PBS. The platelets were washed 53 15minutes with wash buffer (1%
FBS and 0.05%TritonX-100 in PBS) and incubatedwith secondary antibody in
PBS in the presence of 5% FBS and 0.05% Triton X-100 for 1 hour at room
temperature. Finally platelets were washed 5 3 15 minutes with wash buffer,
once in PBS, and postfixed with 4% paraformaldehyde for 10 minutes. After
washing in PBS, coverslips were mounted with VECTASHIELD mounting
medium (Vector Laboratories, Burlingame, CA). Cells were imaged with
a Nikon A1R confocal microscope (Nikon, Melville, NY) with an Apo TIRF
60X/1.49NADICN2oil objective andA1camera. Imageswereprocessedusing
NIS-Elements AR 3.2 software (Nikon) and Photoshop CS5 (Adobe, San Jose,
CA). Digital zooms were either315 or330.
Results
Arf6 KO platelets were defective for Fg storage
Platelet-specific Arf6 KOmice were generated by crossing Arf6flox/flox
mice26with PF4-Cremice.27 Comparedwith their littermates,Arf6KO
mice had similar platelet counts but slightly decreased platelet size
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(;5% decrease; supplemental Table 1). By western blotting, Arf6 was
reduced by ;95% (Figure 1). Other proteins remained unchanged
(Figure 1A), including the following: Arf1/3, Rho family members
(Rac1, Cdc42, and RhoA), granule membrane markers (P-selectin and
VMAT2, a– and dense granules, respectively), and core secretory
machinery (VAMP8, Syntaxin 11, SNAP23, and VAMP3). Arf6 KO
platelets had no defects in aggregation or adenosine triphosphate
release in response to different agonists (supplemental Figure 2A)
and had no gross, morphologic abnormalities (supplemental Figures
2B and 3). To determine whether Arf6 KO mice had thrombosis or
hemostasis defects, tail bleeding and FeCl3-induced carotid artery
injury assays were performed. In supplemental Figure 2C-D, Arf6
KO mice showed no overt bleeding diathesis.
Given the importance of Arf6 in endocytic trafficking, we sought to
determine if Arf6 KO platelets showed any defect in granule content.
Wepaid specific attention to Fg because it is taken up by platelets via an
aIIbb3-mediated endocytosis process.
5 In Figure 1B, endogenous Fg
levels were reduced by;50% in each of the Arf6 KO platelet samples
tested. This defect was not because of alterations in plasma Fg levels
(supplemental Figure 4). Other cargo, derived either from plasma (eg,
immunoglobulinG [IgG]) or from de novo synthesis (eg, platelet factor
4), were not reduced in Arf6 KO platelets (Figure 1C). Of note, there
was no defect in vitronectin (binds aVb3) or fibronectin (binds a5b1
and avb3) level, suggesting that the endocytosis defect is greater for
aIIbb3/Fg. These data suggest thatArf6 plays an important role in either
Fg uptake, storage, or both.
Arf6 KO platelets displayed normal surface aIIbb3 levels and
normal Fg binding
To address the possibility that the defective Fg storage was because of
decreased surface aIIbb3, levels of total and activated aIIbb3 were
measured. In Figure 2A-B, aIIbb3 levels, whether total or activated,
were unaffected in restingor in thrombin-stimulatedArf6KOplatelets
as measured by FACS. These data are consistent with the aggregation
results in supplemental Figure 2A. Thrombin stimulation did
significantly increase total surface aIIbb3, suggesting that a fraction
(;20%) resides in an internal compartment. The possibility that
defective Fg storage was caused by defective Fg binding to Arf6 KO
platelets was also tested by FACS. In Figure 2C, Arf6 KO platelets
have comparable binding capacity for FITC-Fg in both concentra-
tions tested. These data suggest that defective Fg uptake/storage in
Arf6 KO platelets is not the result of either defective binding ability
or decreased surface levels of aIIbb3.
Arf6 KO platelets were defective in Fg uptake in vivo and ex vivo
Fg uptake is seen in both megakaryocytes and platelets.5 To determine
if Arf6 plays a role in platelet Fg uptake, we examined uptake of biotin-
Fg and FITC-Fg. For in vivo assays, biotin-Fg was injected via the
retro-orbital sinus, and platelets were harvested 24 hours postinjection.
The platelet-associated biotin-Fg was analyzed by western blotting.
In Figure 3A, Arf6 KO platelets retained significantly less biotin-Fg
compared with WT. Ex vivo, washed platelets were incubated with
FITC-Fg and fixed for imaging in the presence of trypan blue. In
Figure 3Bi, Arf6 KO platelets had a lower, trypan blue-resistant,
internal pool of FITC-Fg compared with WT platelets. Quantita-
tively, using FITC-labeled puncta number per platelet as a metric,
KO platelets had a higher percentage of cells with fewer puncta
(Figure 3Bii). This deficit was also detectible by flow cytometry at
the earliest time point (5minutes; Figure 3D). These data suggest that
Arf6 deletion could affect intraplatelet trafficking of endocytosed Fg
by redirecting it away from its normal storage site (ie, a-granules).
To determine if uptake of Fg by megakaryocytes contributes to the
storage deficit of Fg in platelets in vivo,WTandKOmicewere injected
with FITC-Fg, via retro-orbital sinus, and bone marrow cells and
platelets were harvested 24 hours postinjection. Megakaryocytes
were identified by anti-CD41 staining. In Figure 3E, FITC-Fg was
undetectable in megakaryocytes from either WT or KO mice,
whereas FITC-Fgwas readily detected inWTplatelets but was lower
in KO platelets. In Figure 3E, the exposure times for FITC-Fg were
twice as long formegakaryocytes as for platelets. This result suggests
that, under our experimental conditions, FITC-Fg uptake by platelets
is more effective than bymegakaryocytes. It should be noted that the
injected FITC-Fg was probably taken up by circulating platelets
before gaining access to the bone marrow cells.
Endocytosed Fg can be routed through multivesicular bodies
(MVBs)before being stored ina-granules.30MVBsare alsoconsidered
an intermediate stage for lysosomal degradation.31 To exclude the
possibility that decreased Fg storage was because of enhanced
Figure 1. Arf6 KO platelets are defective in Fg
storage but not in other cargo. (A) Comparison of
proteins levels by western blotting between wild-type
(WT) and KO platelets. Washed platelet extracts
(1 3 107/lane) were loaded, and the indicated proteins
were probed for by western blotting using the corre-
sponding antibodies. b-Actin was used as a loading
control. The data are representative of at least 3 inde-
pendent experiments. (B) Comparison of endogenous
Fg levels between WT and KO platelets. (i) Washed
platelet extracts (1 3 107/lane) were loaded, and the
indicated proteins were probed for by western blotting
using corresponding antibodies. Each lane represents
platelets from a single mouse. RabGDI was used as a
loading control. (ii) Quantification of Fg levels in panel
Bi was performed using ImageQuantTL and analyzed
by SigmaPlot 12.0. (C) Comparison of granule cargo
levels between WT and KO platelets. Washed platelet
extracts (1 3 107/lane) were loaded, and the indicated
proteins were probed for by western blotting using
corresponding antibodies. b-Actin was used as a
loading control. Quantification was performed using
ImageQuantTL, and ratio of KO to WT was calculated.
The dash line represents ratio of 1 (KO/WT). The
data are representative of at least 2 independent
experiments.
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degradation, we tried to detect fragments of biotin-Fg in samples
from the in vivo uptake assay. Despite overexposing the images,
fragments of biotin-Fg were not detectable in either WT or KO
platelets (Figure 3C). Although the lack of fragments is a negative
result, it is consistent with endocytosed biotin-Fg not being degraded
in platelets lackingArf6. Taken together, these data suggest that Arf6
is required for proper Fg storage in platelets.
Spreading on Fg was enhanced by Arf6 deletion
Because aIIbb3 is the major receptor for Fg uptake and storage,
7
defective Fg storage in Arf6 KO platelets implies defective endocytic
trafficking of aIIbb3. We sought to determine if this altered trafficking
affects other platelet activities, aside fromgranule loading. Examples of
how this could occur include the following: Inhibition of b1 integrin
trafficking by Arf6 deletion in HeLa cells inhibits cell spreading on
fibronectin.32 Alternatively, in neurons, Arf6 inactivation increases
recycling of a9b1 through a Rab4-mediated pathway and increases
axonal growth.19 To investigate roles for Arf6 in aIIbb3-mediated
spreading, we performed time-course studies of platelet spreading on
Fg-coated surfaces. Surprisingly, Arf6 KO platelets spread faster
compared with WT without affecting initial static adhesion (Figure 4).
Arf6 KO platelets had larger surface areas as early as 60 minutes
(Figure 4B). At 90 and 120 minutes, Arf6 KO platelets were
significantly larger than WT (Figure 4B-D).
Arf6 deletion affected platelet clot retraction
Given the enhanced spreading, we asked if other aspects of aIIbb3
function, such as clot retraction were affected. Consistently, Arf6 KO
platelets had enhanced clot retraction (Figure 5A). Fg was added
exogenously and thus is not limiting. The increased clot retraction
supports the contention that loss of Arf6 affects the efficacy of aIIbb3
engagement with substrate. Because downstream signaling by aIIbb3
plays an important role in clot retraction,33,34 tyrosine phosphorylation
profiles (supplemental Figure 5), myosin light-chain phosphorylation
(Figure 5B), F-actin formation (Figure 5C), and Rac1/RhoA activation
(Figure 5D-E) were examined. Surprisingly, there were no overt
differences detected between WT and KO. These data lessen the
possibility that the enhanced clot retraction and spreading pheno-
types are because of some effects on the signaling steps that are
associated with aIIbb3.
Intraplatelet trafficking of FITC-Fg
Previous work showed that Fg is taken up and trafficked to MVBs and
granules.30 Other studies showed that trafficking of integrins in
nucleated cells involves a Rab4-mediated fast route and a Rab11-
mediated slow route.22,24,35 Rab4 and Rab11 are both present in
platelets, and their levelswere unaffectedbyArf6deletion (Figure 1A).
Immunofluorescence analysis showed that Rab41 and Rab111 com-
partments were present but did not overlap, indicating that resting
platelets contained both early and recycling endosomes (Figure 6A).
To monitor Fg trafficking,WT platelets were incubated with FITC-Fg
for increasing times, fixed, and immunostained with anti-Rab4 (early
endosomes)or anti-Rab11 (recycling endosomes) antibodies (Figure 6B).
At the initial timepoints, FITC-FgcolocalizedmoreobviouslywithRab4,
but over time, it also colocalizedwith Rab11. This progression suggests a
transit of endocytosed cargo from early to recycling endosomes. Because
of the lower number of FITC-Fg1 platelets, we were unable to
successfully evaluate Fg trafficking in Arf6 KO platelets. In the
few platelets examined, there was a delay in progression to the
Figure 2. Arf6 deletion does not alter the surface
levels of total or activated integrin aIIbb3 or the
binding of Fg to platelets. (A) Comparison of surface
levels of total integrin aIIbb3 between WT (light gray)
and KO (dark gray) platelets. Using FITC-anti-CD41/61
antibody, levels of total integrin aIIbb3 were measured
by flow cytometry, in resting (i) and thrombin-stimulated
(0.1 U/mL; ii) platelets. Unlabeled platelets (black) were
used as the background control. (iii) Quantification of
flow cytometry data in panels Ai and Aii expressed
as GMFI. The data shown are representative of at
least 2 independent experiments with triplicates.
(B) Comparison of surface levels of activated integrin
aIIbb3 between WT (light gray) and KO (dark gray)
platelets. Using phycoerythrin (PE)–Jon/A antibody,
levels of activated integrin aIIbb3 were measured by
flow cytometry, in resting (i) and thrombin-stimulated
(0.1 U/mL; ii) platelets. Unlabeled platelets (black)
were used as the background control. (iii) Quantification
of flow cytometry data in panels Bi and Bii expressed
as GMFI. Data shown are representative of at least
2 independent experiments with triplicates. (C) Com-
parison of Fg binding to platelet surface between WT
and KO platelets. Washed platelets (5.0 3 108/mL)
were incubated, on ice, with FITC-Fg at different
concentrations for 20 minutes and then fixed with 2%
paraformaldehyde overnight at 4°C. Platelets were
analyzed by flow cytometry, and quantification is shown
as GMFI. The data shown are representative of 2
independent experiments with triplicates.
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Figure 3. Arf6 KO platelets are defective in Fg uptake in vivo and ex vivo. (A) Arf6 deletion impairs platelet uptake of Fg in vivo. (i) WT and KO mice were injected with
biotin-Fg via the retro-orbital sinus. Platelets were harvested 24 hours postinjection. Platelet extracts (13 107/lane) were loaded, and the indicated proteins were probed for by
western blotting using corresponding antibodies. Each lane represents platelets from a single mouse. A mouse without injection (No Inj) was included as a negative control.
b-Actin was used as a loading control. (ii) Quantification of biotin-Fg levels in panel Ai was performed using ImageQuantTL and analyzed by SigmaPlot 12.0. (B) Arf6 deletion
impairs Fg uptake by platelets ex vivo. (i) Washed platelets (53 108/mL) from WT and KO mice were incubated with FITC-Fg (0.05 mg/mL) for 1 hour at 37°C. After removing
the extracellular FITC-Fg, platelets were incubated with HEPES Tyrode buffer (pH5 7.4) for another 2 hours. Platelets were fixed with 2% paraformaldehyde overnight at 4°C
and subjected to epifluorescence microscopy. The extracellular signal was quenched with 0.1% trypan blue, and representative images, from 4 experiments, are presented.
(ii) The number of FITC-positive puncta per platelet was manually counted, and platelets were grouped according to that number. The percentage platelets in each group
relative to total was calculated and plotted as a bar graph. Statistical significance was determined using rank sum test. (C) Overexposure of biotin blot in panel Ai, to probe for
fragments of biotin-Fg. Starting biotin-Fg (Pre Inj) was included as a comparison. (D) Arf6 deletion impedes uptake of FITC-Fg ex vivo. Washed platelets (1.0 3 109/mL) from
3 WT (black) and 3 KO (open) mice were separately incubated with FITC-Fg (0.15 mg/mL) at 37°C for the indicated times and then fixed with 2% paraformaldehyde overnight
at 4°C. Intracellular FITC-Fg levels were measured by flow cytometry, after addition of trypan blue, and expressed as GMFI (mean 6 standard deviation). Statistical
significance was determined by Student t test. (E) Megakaryocyte uptake of FITC-Fg is below detection under the conditions used. WT and KO mice were injected with
FITC-Fg (0.75 mg/mouse) via the retro-orbital sinus. Each group included 2 mice. Bone marrow cells and platelets were harvested 24 hours postinjection and fixed with 2%
paraformaldehyde. DIC images and fluorescence images are presented. Megakaryocytes were identified by CD41 staining. (i) The exposure time for FITC-Fg and CD41
images is 2 seconds and 0.5 seconds, respectively. The scale bar is 10 mm. (ii) The exposure time for FITC-Fg is 1 second. The scale bar represents 5 mm. Representative
images were selected from .10 different fields of each group.
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Rab111 compartment, but this will require more analysis to confirm
(data not shown).
Discussion
In this study, we found that deletion of a small GTPase, Arf6, in
platelets, resulted indefectiveFguptake and storage (Figures 1Band3).
Fg, bound at the surface, was apparently not transported to its proper
storage site(s). Because aIIbb3 is the major receptor for Fg uptake
5 and
its levels were normal in Arf6 KO platelets (Figure 1A), our data
suggest a role for Arf6 in intraplatelet trafficking ofaIIbb3. Intracellular
trafficking of integrins affects cell adhesion and migration and may
affect platelet activity. Loss of Arf6 had no significant effects on the
expression of other proteins (Figure 1A), nor was there any overt
morphology defect (supplemental Figure 2B). Flow cytometry analysis
confirmed that there were no detectible defects in total or activated
levels of surface aIIbb3 (Figure 2A-B). Fg binding also appeared
normal (Figure 2C). Consistently, agonist-induced platelet aggregation
and adenosine triphosphate release were unaffected (supplemental
Figure 2A). Surprisingly, Arf6 loss enhanced platelet spreading on Fg
and clot retraction; however, these effects were insufficient to
significantly alter thrombus formation or hemostasis. The simplest
interpretation of our data is that Arf6 affects Fg uptake and, by
extension, aIIbb3 trafficking in platelets. One can surmise that the
;50% reduction in Fg uptake is not detrimental in the thrombosis
and hemostasis models tested. Our data imply that aIIbb3 trafficking
contributes to platelet spreading and clot formation, which is
consistent with the roles of integrin trafficking in migrating cells.
It is well-established that platelets and megakaryocytes do not
synthesize Fg and that the Fg, stored in platelets, accumulates via a
receptor-mediated endocytosis process with aIIbb3 as its receptor.
7
Platelet aIIbb3 levels (Figure 1A) and plasma Fg levels (supplemental
Figure 4) were normal in the Arf6 KOmice. As a possible explanation
for our data, binding of Fg to aIIbb3 could be less stable in Arf6 KO
platelets, resulting in less efficient endocytosis. However, Fg binding to
aIIbb3 appeared unaffected (Figure 2C). Defective Fg storage, in Arf6
KO platelets, could result from mistargeting of endocytosed Fg into a
degradative compartment. However, we failed to detect any biotin-Fg
fragments (Figure 3C). Western blotting for other a-granule cargo and
membrane proteins did not uncover any overt defects in granule
biogenesis (Figure 1C). Thus, our data are most consistent with the
defect in Fg uptake or storage in Arf6 KO platelets being because of
either defective endocytosis or altered Fg/aIIbb3 trafficking.
Integrin endocytosis and recycling are essential for adhesion and
cellmigration.23,24Arf6 affects the routingbetween2 integrin recycling
pathways: a Rab4-mediated fast-recycling pathway and a Rab11-
mediated slow-recycling pathway.19,22 Rab4 andRab11 are present but
did not colocalize suggesting that platelets contain both early and
recycling endosomes (Figure 6A). Endocytosed Fg did gain access to
both compartments, over time, inWTplatelets (Figure 6B). A potential
explanation for the Arf6 KO platelet phenotype is a redirection of
Fg/aIIbb3 into a Rab4-mediated fast pathway, reducing aIIbb3’s
internal residence time and resulting in less Fg being retained within
the platelets. This hypothesis is consistent with our observations in
Figure 3B,D, whereArf6KOplatelets contain lower levels of FITC-
Fg in fewer punctate structures. Although we cannot directly
exclude a defect in endocytosis, FITC-Fg was detected in internal
punctate structures suggesting that bulk-phase endocytosis may still
occur in the absence of Arf6. Other endocytosed cargo were
unaffected (Figure 1C). To fully define the role of Arf6 in aIIbb3
trafficking and the routes possible, extensive high-resolution
imaging analysis will be needed. However, our present data are
consistent with previous studies that platelets do contain sorting
compartments, such as MVBs,30 which are known to be part of
normal endocytic routes.
Given the proposed role of Arf6 in aIIbb3 trafficking, we were
surprised that flow cytometry analysis (Figure 2A-B) showed little
alterations in the surface levels of aIIbb3 in the Arf6 KO platelets.
Because our FACS assays are static measurements, reflecting steady-
state levels of surface aIIbb3, they may not report on small populations
Figure 4. Arf6 KO platelets have enhanced spread-
ing but normal static adhesion. (A) Quantification of
static platelet adhesion on Fg- and BSA-coated surface.
Washed calcein-labeled platelets (2.5 3 108/mL) from
WT and KOmouse were incubated on Fg- or BSA-coated
surfaces for 30 minutes at 37°C. The number of adherent
platelets was measured using a plate reader with
excitation/emission at 485/538 nm, and referenced to a
standard curve. Each bar represents platelets from a
single mouse. Statistical analysis was performed using
Student t test. (B) Quantification of platelet surface area
when spread on Fg-coated surfaces. Washed platelets
from WT and KO mice (2.0 3 107/mL) were supple-
mented with 1 mM Ca21 and then incubated on Fg-
coated surfaces for the indicated times. They were
fixed with 4% paraformaldehyde, and DIC images were
taken using Nikon Eclipse E600 microscope (Nikon)
with a 100X/1.40 NA, DIC H oil objective lens (Nikon)
with a Zeiss camera (AxioCam MR). Images were
processed with Zen 2011 (blue edition; Zeiss) and
quantified by Image J (v1.47; National Institutes of
Health). (C-D) Representative DIC images of WT (C)
and KO (D) platelets spread at the 120 minutes point.
The data are representative of at least 3 independent
experiments.
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Figure 5. Arf6 KO platelets have enhanced platelet clot retraction without noticeable defect on myosin light-chain phosphorylation (MLC-P), actin polymerization,
or Rac1/RhoA activation. (A) Washed platelets from WT and KO mice (33 108/mL) were supplemented with 0.5 mg/mL human Fg and 1 mM Ca21. Clot retraction was initiated
with thrombin (0.1 U/mL), and images were taken at the indicated times (i) and quantified (ii). Clot size in panel A was measured using Image J v1.48 and normalized to clot size at
time 0 (clot volume %). The data are representative of at least 5 independent experiments. (B) KO mice showed no defect in MLC-P upon thrombin stimulation. Washed platelets
from WT and KO mice were prepared at 43 108/mL in HEPES Tyrode buffer (pH 7.4) and kept resting or stimulated with thrombin (0.1 U/mL) for the indicated times. The reaction
was stopped by addition of sodium dodecyl sulfate–polyacrylamide gel electrophoresis sample buffer containing both protease inhibitor and phosphatase inhibitor cocktails. The
lysates were probed for MLC-P by western blotting. b-Actin was used as a loading control. The blots shown are representative of at least 3 independent experiments. (C) Arf6
deletion did not affect thrombin-induced F-actin formation. Resting and thrombin-stimulated platelets (2 3 107) were fixed and permeabilized with Triton X-100 in the presence of
tetramethylrhodamine (TRITC)-phalloidin. The bound TRITC-phalloidin was solubilized and measured using a microplate spectrofluorimeter. The data are representative of 2
independent experiments. (D-E) KO platelets showed no defect in Rac1/RhoA activation. Washed platelets (53 108/mL) fromWT and KOmice were kept resting or stimulated with
thrombin (0.1 U/mL) for the indicated times. The reactions were stopped by addition of 23GTPases-pulldown lysis buffer containing a protease inhibitor cocktail. Rac1-GTP/RhoA-
GTP were recovered as described in “Methods.” (Di and Ei) Western blotting of the pellets (Rac1-GTP or RhoA-GTP) and the supernatant (total Rac1 or total RhoA). (Dii and Eii)
Quantification of Rac1-GTP/total Rac1 and RhoA-GTP/total RhoA. Quantification was performed using ImageQuantTL, and the ratio of Rac1-GTP/total Rac1 or RhoA-GTP/total
RhoA was plotted in a bar graph. Blots shown are representative of at least 2 independent experiments.
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of aIIbb3 that rapidly recycle on and off the plasma membrane. Arf6
depletion did not affect the platelet signaling steps examined
(Figure 5B-E and supplemental Figure 5), which contradicted our
previous studies of human platelets using acylated peptides as Arf6
inhibitors.12 The myr-Arf6 peptide, compared with a myr-Arf1
peptide, inhibited uptake of FITC-Fg by human platelets (sup-
plemental Figure 6B); however, mouse platelets were not
sensitive to either acylated peptide (supplemental Figure 6A), so
it is possible that there are some off-target effects for the myr-Arf6
peptide’s actions. It should be noted that mouse and human platelets
contain different amounts of GIT1 (supplemental Figure 7), an Arf6
GTPase-activating protein, which could account for these species
differences. Additional studies are underway to understand the
effects of the acylated Arf6 peptides.
Because Arf6 could affect the endocytic trafficking of aIIbb3, Arf6
depletion was expected to affect the platelet functions related to aIIbb3.
Indeed, Arf6 deficiency enhanced platelet spreading on Fg-coated
surfaces and promoted platelet clot retraction (Figures 4B-Dand 5A). If
activatedaIIbb3 was recyclingmore rapidly in Arf6KO platelets, more
might be available tomake contacts with Fg. This scenario is consistent
with our previous findings regarding changes in Arf6-GTP/GDP levels
in resting vs activated platelets.12,13 Resting human andmouse platelets
have higher, active Arf6-GTP levels (perhaps a consequence of
involvement in trafficking). Arf6-GTP decreases precipitously to Arf6-
GDP upon platelet activation, and Arf6-GDP levels are maintained via
an integrin-mediated process that requires Src family kinases and
outside-in signaling.13 This “inactivated” state ismimicked byArf6
deletion. During normal platelet activation, active Arf6-GTPmay be
reduced to promote spreading. Outside-in signaling in the spreading
platelet suppresses recovery of Arf6-GTP to prolong spreading. The
enhanced spreading phenotype appeared specific for Fg because itwas
not detected on other coated surfaces (supplemental Figure 8). Based
on the spreading and clot retraction phenotype, we expected that the
Arf6 KOmice should be hyperthrombotic; however, that was not detected
in the 2 assays used. This would suggest that the enhancements of
spreading and clot retraction are not sufficient to cause robust
alterations in clot formation in vivo.
Our studies represent some of the first mechanistic analyses of
endocytosis by platelets. Although recognized, for ;30 years, as a
process to load granules with Fg,18,36 our data imply more acute
functions for endocytosis in clot formation. A refined role for such
platelet endocytosis is still unclear; however, one could envision the
endocytic trafficking of integrins being involved in modulating
interplatelet connections in a growing thrombus. Also, although still
uncharacterized, it would seem possible that platelets maymigrate in
the forming clot, and thus endocytic trafficking of cell surface integrins
may play a role in that process as it does in migrating, nucleated cells.
Themicewe characterized in thismanuscript will assist in the continued
study of such processes and in the determination of their relevance to
thrombosis.
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